TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers at WEHI identified gamma delta T cells in small cell lung cancer and found the cells could kill tumor cells in patient-derived laboratory models. Existing drugs strengthened that response in experiments, while patient data linked higher cell levels with longer survival; whether the approach benefits patients remains untested.
Researchers at WEHI have identified gamma delta T cells that can recognize and kill small cell lung cancer in laboratory models, and reported that two existing medicines strengthened the cells’ cancer-fighting activity in experiments. The study, published in Cancer Cell, also found that patients whose tumors contained more of these immune cells tended to survive longer, but it does not establish that the approach improves survival or treatment outcomes.
To test whether the immune cells could attack the cancer directly, the researchers created miniature tumors from tissue samples donated by patients. The samples came through the Victorian Cancer Biobank in partnership with the Royal Melbourne Hospital. The team added gamma delta T cells collected from the same patients’ blood and observed the cells identifying and destroying cancer cells in the models.
The researchers then tested tarlatamab, an existing small cell lung cancer treatment, and zoledronate, a medicine used for osteoporosis and cancer-related bone disease. In the laboratory experiments, zoledronate increased the number of gamma delta T cells available and improved their ability to identify tumors. Tarlatamab helped bring the immune cells into contact with cancer cells. Used together, the medicines increased cancer-cell killing by the immune cells.
The study also examined patient tumor data. Patients with greater numbers of gamma delta T cells in their tumors tended to have longer survival, according to the researchers. That association does not show that the cells caused the difference, or that increasing their numbers through treatment would extend patients’ lives. The supplied report does not provide the patient cohort size or survival estimates.
A Route Around Tumor Evasion
Small cell lung cancer is difficult to treat in part because tumors can evade immune surveillance. Many immunotherapies rely on conventional immune cells recognizing cancer, and the report says lasting benefits from immunotherapy remain limited for this disease. The findings point to a potential alternative: gamma delta T cells may detect and attack tumors that escape some conventional immune responses.
The proposed drug combination could matter because it uses medicines already in clinical use to strengthen the activity of these cells in laboratory models. Researchers also raised the possibility of adoptive cell transfer, in which immune cells are collected, multiplied outside the body and returned to the patient. Such approaches could eventually add to treatment options, but the experiments reported here are an early step, not evidence of a ready-to-use therapy.
small cell lung cancer patient guide book
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Small Cell Lung Cancer Resists Treatment
Small cell lung cancer (SCLC) is described in the report as one of the deadliest cancers, with fewer than 7% of patients surviving five years after diagnosis. The article attributes part of the treatment challenge to the cancer’s ability to avoid detection by conventional immune cells. Immunotherapy has improved outcomes in several cancers, but its benefits in SCLC have been more limited, with lasting responses occurring in only a minority of patients.
The new study, led by researchers at WEHI, examined whether another immune-cell population could recognize the disease. Gamma delta T cells are the focus of the report because the researchers found them in SCLC tumors and observed them attacking cancer cells in patient-derived models. The work was published in Cancer Cell in October 2026, according to the source material.
“For decades, we’ve known that small cell lung cancer is exceptionally good at hiding from the immune system. We’ve found an immune cell that appears to be able to see through that disguise.”
— Professor Kate Sutherland, the study’s senior author and a laboratory head at WEHI
lung cancer caregiver support workbook
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Patient Benefit Remains Unproven
The reported tumor-killing results came from laboratory models, not a clinical trial showing that the drug combination or transferred gamma delta T cells are safe and effective in people with SCLC. The source material does not give trial results, dosing details, side-effect findings or a timeline for testing the approach in patients.
It is also unclear how many patients were included in the survival analysis, how large the difference was, or whether other factors explain why patients with more gamma delta T cells tended to live longer. The report describes an association, not proof of a treatment effect. It also does not establish which patients might benefit, or whether the two medicines would work together safely and effectively in clinical care.
lung cancer symptom and treatment journal
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Testing the Approach in Patients
The next key step would be clinical research to determine whether the laboratory findings translate into patient benefit. Studies would need to assess safety and effectiveness, including whether zoledronate and tarlatamab can strengthen gamma delta T-cell activity in people and whether cell-transfer strategies can be used against SCLC.
The supplied report does not announce a clinical trial or provide a start date. Researchers have described existing methods to expand and reinfuse gamma delta T cells as a possible route toward treatment development, but whether and when the approach will be tested in patients remains unclear.
As an affiliate, we earn on qualifying purchases.
Key Questions
What immune cells did the researchers identify?
The study focused on gamma delta T cells, an immune-cell population the researchers found in small cell lung cancer tumors and observed attacking cancer cells in laboratory models.
Did the study show that the drugs treat lung cancer patients?
No. The reported increase in cancer-cell killing came from laboratory experiments. The source does not report a clinical trial showing that the combination improves outcomes for patients.
Which medicines were tested?
The researchers tested tarlatamab, an existing treatment for small cell lung cancer, and zoledronate, which is used for osteoporosis and cancer-related bone disease. The report says they strengthened gamma delta T-cell activity in the lab through different effects.
What does the survival finding mean?
Patients whose tumors contained more gamma delta T cells tended to survive longer, according to the study report. That is an association; it does not prove the cells caused longer survival or that a therapy to increase them would do so.
What happens before this could become a treatment?
Clinical studies would need to test safety and effectiveness in patients. The source material does not confirm that a trial has begun or give a timeline for testing the approach.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
